Biontech Se Stock Performance
| BNTX Stock | USD 112.89 1.03 0.90% |
On a scale of 0 to 100, BioNTech holds a performance score of 4. The firm shows a Beta (market volatility) of 1.04, which signifies a somewhat significant risk relative to the market. BioNTech returns are very sensitive to returns on the market. As the market goes up or down, BioNTech is expected to follow. Please check BioNTech's maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether BioNTech's price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in BioNTech SE are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, BioNTech showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.90) | Five Day Return 2.16 | Year To Date Return (2.09) | Ten Year Return 692.77 | All Time Return 692.77 |
Dividend Date 2022-06-17 | Ex Dividend Date 2022-06-02 |
1 | BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion | 05/05/2025 |
2 | BioNTech SE Among the Best Growth Stocks to Buy and Hold for the Long Term | 05/14/2025 |
3 | BNTX Stock News COVID Vaccine Recommendation Update BNTX Stock News | 05/27/2025 |
4 | BioNTech soars 15 percent on cancer drug deal with Bristol Myers | 06/02/2025 |
5 | Truist Lifts BioNTech Price Target After New Partnership | 06/03/2025 |
6 | Micron To Rally Around 26 Here Are 10 Top Analyst Forecasts For Thursday | 06/05/2025 |
7 | RFK Jr.s firing of CDC vaccine advisors circumvents science and could threaten public health, experts say | 06/10/2025 |
8 | BioNTech To Acquire CureVac In All-stock Deal With Aggregate Equity Value Of Approx. 1.25 Bln - Nasdaq | 06/12/2025 |
9 | CureVac Soars 41 percent in a Month on a 1.25B Buyout Offer From BioNTech - Zacks Investment Research | 06/20/2025 |
10 | BioNTech ADR Gets Relative Strength Rating Upgrade - Investors Business Daily | 06/27/2025 |
11 | Recent Agreements Set To Bolster BioNTech SE s Oncology Arm - Insider Monkey | 07/09/2025 |
| Begin Period Cash Flow | 11.7 B |
BioNTech Relative Risk vs. Return Landscape
If you would invest 10,234 in BioNTech SE on April 13, 2025 and sell it today you would earn a total of 1,055 from holding BioNTech SE or generate 10.31% return on investment over 90 days. BioNTech SE is currently generating 0.2357% in daily expected returns and assumes 3.9864% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than BioNTech, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioNTech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioNTech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioNTech SE, and traders can use it to determine the average amount a BioNTech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0591
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BNTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.99 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.24 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average BioNTech is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioNTech by adding it to a well-diversified portfolio.
BioNTech Fundamentals Growth
BioNTech Stock prices reflect investors' perceptions of the future prospects and financial health of BioNTech, and BioNTech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioNTech Stock performance.
| Return On Equity | -0.0394 | ||||
| Return On Asset | -0.0367 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (2.70) % | ||||
| Current Valuation | 10.93 B | ||||
| Shares Outstanding | 240.4 M | ||||
| Price To Earning | 5.19 X | ||||
| Price To Book | 1.23 X | ||||
| Price To Sales | 9.97 X | ||||
| Revenue | 2.75 B | ||||
| Gross Profit | 2.18 B | ||||
| EBITDA | (367.1 M) | ||||
| Net Income | (677.7 M) | ||||
| Cash And Equivalents | 9.33 B | ||||
| Cash Per Share | 38.30 X | ||||
| Total Debt | 254.2 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 5.15 X | ||||
| Book Value Per Share | 78.73 X | ||||
| Cash Flow From Operations | 207.7 M | ||||
| Earnings Per Share | (3.70) X | ||||
| Market Capitalization | 27.39 B | ||||
| Total Asset | 22.53 B | ||||
| Retained Earnings | 19.1 B | ||||
| Working Capital | 16.28 B | ||||
| Current Asset | 284.67 M | ||||
| Current Liabilities | 143.37 M | ||||
About BioNTech Performance
Evaluating BioNTech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if BioNTech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioNTech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 191.08 | 200.64 | |
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.07) | (0.06) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.03) | (0.03) |
Things to note about BioNTech SE performance evaluation
Checking the ongoing alerts about BioNTech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioNTech SE help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioNTech SE had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 2.75 B. Net Loss for the year was (677.7 M) with profit before overhead, payroll, taxes, and interest of 2.18 B. | |
| About 63.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Recent Agreements Set To Bolster BioNTech SE s Oncology Arm - Insider Monkey |
- Analyzing BioNTech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioNTech's stock is overvalued or undervalued compared to its peers.
- Examining BioNTech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioNTech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioNTech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioNTech's stock. These opinions can provide insight into BioNTech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioNTech Stock Analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.